There are no ethical barriers to including a control group.
The idea that double-blind, placebo-controlled trials are impossible with psychoactive medication is a strawman argument, because obviously we can still have a control group.
The control group doesn't even need to receive placebo. In a study like this one, they could have easily and ethically had one group receive therapy and a second group receive therapy plus mushrooms. Or the first group could have received therapy plus traditional SSRIs.
The placebo response rate in antidepressant studies is extraordinarily high. There is no good reason to omit a control group in studies like these, other than perhaps if the researchers were too underfunded to make it work.